Eliana Merle
Stock Analyst at Barclays
(3.54)
# 780
Out of 5,152 analysts
106
Total ratings
47.56%
Success rate
6.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $80 → $105 | $60.57 | +73.35% | 4 | Mar 4, 2026 | |
| TPG TPG Inc. | Maintains: Overweight | $69 → $56 | $44.96 | +24.56% | 2 | Mar 2, 2026 | |
| GOSS Gossamer Bio | Downgrades: Underweight | $9 → $0.3 | $0.52 | -42.51% | 5 | Feb 24, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $606 → $607 | $460.82 | +31.72% | 2 | Feb 17, 2026 | |
| QURE uniQure | Initiates: Equal-Weight | $31 | $10.65 | +191.08% | 5 | Jan 28, 2026 | |
| TYRA Tyra Biosciences | Initiates: Overweight | $59 | $34.54 | +70.82% | 2 | Jan 28, 2026 | |
| SGMT Sagimet Biosciences | Initiates: Equal-Weight | $8 | $5.45 | +46.79% | 2 | Jan 28, 2026 | |
| PTCT PTC Therapeutics | Upgrades: Overweight | $68 → $119 | $63.33 | +87.90% | 1 | Jan 28, 2026 | |
| MBX MBX Biosciences | Initiates: Overweight | $66 | $31.44 | +109.96% | 1 | Jan 28, 2026 | |
| MDGL Madrigal Pharmaceuticals | Initiates: Overweight | $964 | $439.34 | +119.42% | 6 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $6.05 | +197.52% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $231 | $143.57 | +60.90% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $342 | $237.35 | +44.09% | 3 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $8.64 | +281.94% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $80 | $66.17 | +20.90% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $24 | $20.15 | +19.11% | 9 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $527 | $320.51 | +64.43% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $40 → $34 | $53.83 | -36.84% | 9 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $3.51 | +584.74% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $57.28 | -65.08% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $16.23 | -26.06% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $2.35 | +240.43% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $13.72 | +53.06% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $83.52 | -16.19% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $2.19 | +0.69% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $99.64 | -28.74% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $101.95 | +28.49% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $25.16 | -80.13% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $42.00 | -57.14% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $17.95 | +22.56% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $8.72 | +438.99% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $14.33 | +11.65% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $33.38 | +301.44% | 3 | Aug 19, 2020 |
BioMarin Pharmaceutical
Mar 4, 2026
Maintains: Overweight
Price Target: $80 → $105
Current: $60.57
Upside: +73.35%
TPG Inc.
Mar 2, 2026
Maintains: Overweight
Price Target: $69 → $56
Current: $44.96
Upside: +24.56%
Gossamer Bio
Feb 24, 2026
Downgrades: Underweight
Price Target: $9 → $0.3
Current: $0.52
Upside: -42.51%
Vertex Pharmaceuticals
Feb 17, 2026
Maintains: Overweight
Price Target: $606 → $607
Current: $460.82
Upside: +31.72%
uniQure
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $31
Current: $10.65
Upside: +191.08%
Tyra Biosciences
Jan 28, 2026
Initiates: Overweight
Price Target: $59
Current: $34.54
Upside: +70.82%
Sagimet Biosciences
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $8
Current: $5.45
Upside: +46.79%
PTC Therapeutics
Jan 28, 2026
Upgrades: Overweight
Price Target: $68 → $119
Current: $63.33
Upside: +87.90%
MBX Biosciences
Jan 28, 2026
Initiates: Overweight
Price Target: $66
Current: $31.44
Upside: +109.96%
Madrigal Pharmaceuticals
Jan 28, 2026
Initiates: Overweight
Price Target: $964
Current: $439.34
Upside: +119.42%
Jan 28, 2026
Initiates: Overweight
Price Target: $18
Current: $6.05
Upside: +197.52%
Jan 28, 2026
Initiates: Overweight
Price Target: $231
Current: $143.57
Upside: +60.90%
Jan 28, 2026
Initiates: Overweight
Price Target: $342
Current: $237.35
Upside: +44.09%
Jan 28, 2026
Initiates: Overweight
Price Target: $33
Current: $8.64
Upside: +281.94%
Jan 28, 2026
Initiates: Overweight
Price Target: $80
Current: $66.17
Upside: +20.90%
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $24
Current: $20.15
Upside: +19.11%
Jan 28, 2026
Initiates: Overweight
Price Target: $527
Current: $320.51
Upside: +64.43%
Jan 7, 2026
Assumes: Neutral
Price Target: $40 → $34
Current: $53.83
Upside: -36.84%
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $3.51
Upside: +584.74%
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $57.28
Upside: -65.08%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $16.23
Upside: -26.06%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.35
Upside: +240.43%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $13.72
Upside: +53.06%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $83.52
Upside: -16.19%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $2.19
Upside: +0.69%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $99.64
Upside: -28.74%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $101.95
Upside: +28.49%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $25.16
Upside: -80.13%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $42.00
Upside: -57.14%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $17.95
Upside: +22.56%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $8.72
Upside: +438.99%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $14.33
Upside: +11.65%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $33.38
Upside: +301.44%